

Elpiscience Announces the Appointment of Jason John Luke, M.D., to its Scientific Advisory Board

Shanghai, Suzhou, China April 3, 2024, Elpiscience announces the Appointment of Jason John Luke, M.D., to its Scientific Advisory Board.

“We are excited to have Dr. Luke join our SAB,” said Dr. Hongtao Lu, Co-Founder and Chief Scientific Officer of Elpiscience. “Dr. Luke’s expertise in clinical and translational immunotherapy as well as his experience in early-stage drug development for solid tumors complement our existing group of renowned scientific experts.”

Dr. Luke is an Associate Professor of Medicine at the University of Pittsburgh and Director of the Immunotherapy and Drug Development Center as well as the Associate Director for Clinical Research at the UPMC Hillman Cancer Center. Previously he was an Assistant Professor of Medicine at the University of Chicago, Attending Physician in Brigham and Women’s Hospital in Boston, and Instructor in Medicine at Harvard Medical School.

Dr. Luke earned his Doctor of Medicine from the Rosalind Franklin University of Medicine and Science/Chicago Medical School and obtained the Bachelor degree of Microbiology in University of Iowa. He completed his training as the resident at Boston University Medical Center. Dr. Luke undertook the fellowship of medicine at Weill Cornell Medical Center, New York and the fellowship of Medical Oncology at Memorial Sloan-Kettering Cancer Center, New York.

About Elpiscience’s Scientific Advisory Board

Dr. Thomas Gajewski from the University of Chicago
Dr. Philip D. Greenberg from the University of Washington
Dr. Jason John Luke from the University of Pittsburgh
Dr. Vijay Kuchroo from Harvard Medical School
Dr. Arlene Sharpe from Harvard Medical School